Company ProfilePremium

Takasago International Corporation

Company Profile Analysis

Ticker: 4914.T高砂香料工業株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Takasago International Corporation - Food & Beverages showcase

Year Founded & Workforce

1920

4,154 Employees

Industry

Food & Beverages
Takasago International Corporation logo

Takasago International Corporation Employee Contacts

42 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Takasago International Corporation Overview

MetricFY2022FY2023FY2024FY2025
Employees (headcount, approx, company-derived)3,9133,9134,0414,154

Takasago International is Japan's largest flavor and fragrance (F&F) house and one of the few globally scaled F&F companies headquartered outside Europe and the United States. Founded in 1920, it combines a conventional creative-led F&F business — flavors for beverages, dairy, savory and oral care, and fragrances for fabric care, home care, personal care and fine fragrance — with an unusually deep chemistry franchise. Its asymmetric-synthesis capability, developed with Nobel laureate Ryōji Noyori, underpins world-scale l-menthol and cooling-agent production and a fine-chemicals business supplying pharmaceutical intermediates and chiral catalysts. Roughly two-thirds of sales are generated outside Japan across 28 countries and regions. Takasago sits in the second tier of the global industry, well behind Givaudan, dsm-firmenich, IFF and Symrise in scale, and its operating margins (3–7%) are structurally below the 18–24% EBITDA margins of the leaders. The investment case therefore rests on margin repair, fine-chemicals recovery and balance-sheet efficiency.


What the company does

Takasago creates, manufactures and sells four product families:

  1. Flavors — taste systems for beverages (its strongest category in Japan and China), dairy, confectionery, savory foods, processed foods, and oral-care products such as toothpaste and mouthwash.

  2. Fragrances — fragrance compounds for consumer products (fabric care, laundry detergents, softeners, home care, air care, hair care, soaps, bath and body, cosmetics) and fine fragrance (perfumes and colognes).

  3. Aroma Ingredients — synthetic aroma chemicals, most notably l-menthol produced by asymmetric synthesis, cooling agents ("sensates"), and specialty aroma molecules, sold both to other F&F houses and used internally.

  4. Fine Chemicals — pharmaceutical intermediates (including GMP intermediates), chiral/asymmetric catalysts and ligands, and materials for the electronics industry (photoconductive / organic electronic materials historically).

A fifth reporting line, Others, comprises principally real-estate leasing income (¥1.4bn sales; ¥1.2bn operating profit in FY2025).

Company's own description (paraphrased from disclosures)

In its FY2025 Tanshin narrative, the company describes itself as promoting its medium-term management plan "New Global Plan-2 (NGP-2)" (FY2024–FY2026) under a slogan built on caring for people and respecting the planet, and as Japan's leading flavor-and-fragrance manufacturer operating the Flavor, Fragrance, Aroma Ingredients and Fine Chemicals businesses in 28 countries and regions, generally serving local demand through local operations (Shared Research profile, updated June 2026; Q3 FY2025 Tanshin, 13 February 2026). JCR's rating releases describe Takasago as Japan's largest flavor and fragrance manufacturer, with steady earnings capacity and a sound financial standing.

Business model and revenue model

DimensionCharacterisation
Revenue model~99% product sales (B2B ingredient sales by weight/volume); ~0.6% real-estate rental income. No material subscription or licensing revenue disclosed
Product vs serviceProduct. "Creation" and application services (perfumers, flavorists, sensory testing) are bundled into the product price rather than billed separately
Pricing basisBespoke compounds priced per kilogram under customer briefs; aroma chemicals and fine chemicals priced on contract/market basis. Raw-material pass-through via periodic price adjustments (management assumes ¥5.0bn of "improvements (e.g., price adjustments)" in FY2026)
Customer economicsEnvalith (July 2026) characterises the model as continuous small-lot supply of a very wide variety of compounds tailored to customer product development, yielding stable, recurring revenue once a fragrance/flavor is "designed in" to a consumer product
Value-chain positionMid-stream: buys natural and petrochemical raw materials (essential oils, terpenes, citral, aroma intermediates), synthesises key molecules in-house (backward integration in menthol and specialty aroma chemicals), and sells compounds to consumer goods and food & beverage manufacturers
Customer typesMultinational and regional FMCG companies (home & personal care), beverage and food manufacturers, oral-care companies, fine-fragrance houses, other F&F companies (for aroma ingredients), pharmaceutical companies (for intermediates)
End-marketsBeverages, dairy, savory/processed foods, confectionery, oral care, fabric care, home and air care, hair and personal care, fine fragrance, pharmaceuticals, electronics

Independent characterisation

Takasago is best understood as a hybrid of a mid-sized creative F&F house and a specialty chiral-chemistry company. The creative businesses (Flavor + Fragrance = 88% of FY2025 sales) are scale-disadvantaged versus the global leaders and earn thin operating margins (4.2% and 0.8% respectively in FY2025). The chemistry businesses (Aroma Ingredients + Fine Chemicals = 11% of sales) historically delivered a disproportionate share of profit — in FY2024 they produced ¥7.0bn of the ¥15.3bn group operating profit (46%) on just 15% of sales — but are volatile, being exposed to single-customer pharmaceutical programmes and menthol raw-material cycles. FY2024's record profit and FY2025's 47% profit decline are almost entirely explained by swings in Fine Chemicals shipments (−¥5.2bn operating profit swing) and the US subsidiary.

Geographically the company is unusually balanced for a Japanese chemicals company: Japan 34%, Americas 25%, EMEA 19%, Asia Pacific 22% of FY2025 segment sales; overseas customer sales were ¥148.1bn (66%) per the Annual Securities Report as summarised by Envalith.

Strategy

Stated strategy

Vision 2040: the long-term vision framing Takasago's growth; Mizuno has said he will build on the foundation laid by Masumura, treat global business-environment changes as growth opportunities, and accelerate initiatives that strengthen long-term foundations, create new value and drive sustainable growth (Cosmetics & Toiletries, June 2026).

NGP-2 (New Global Plan-2), FY2024–FY2026: the current medium-term plan, run under a slogan around caring for people and respecting the planet (Q3 FY2025 Tanshin). Themes include overseas expansion and company-wide transformation (Chemical Weekly, April 2024).

"Unlock growth and expand": fragrance strategy illustrated by the Dubai capability to access MENA and beyond (Cosmetics & Toiletries, 2026).

Innovation pillars: "emotion, performance and green chemistry" across categories and markets; recognition of AI's growing role in market research, fragrance creation/reformulation and ingredient development; sustainable sourcing of naturals and decarbonisation as enduring priorities, noting that many customers have 2030 carbon targets.

NGP-2 capital-policy targets vs actuals

KPIFY2024 actualFY2025 actualFY2026FNGP-2 target
ROE9.8%6.4%6.0%≥8.0%
Equity ratio55.0%56.6%53.4%55% (final year)
Policy-held shares / net assets13.5%12.8%12.5%10% (final year)
DOE (dividend on equity)3.4%3.4%3.3%≥3.0%
Dividend payout ratio35.1%53.2%53.9%≥30%
DPS (post-split)¥48¥52¥52≥¥48

Source: FY2025 Supplemental Information, 15 May 2026. Management signals that ROE (6.0% forecast) and policy-shareholding reduction (12.5% vs 10%) will miss NGP-2 targets, while shareholder-return targets are met or exceeded. The briefing also references a cumulative operating-income target for the plan, which on the trajectory (FY2024 ¥15.3bn + FY2025 ¥8.1bn + FY2026F ¥11.0bn = ¥34.4bn) is unlikely to be achieved; the exact target figure was not captured.

Strategic initiatives (last 24 months)

InitiativeDateDetailStatus
India taste centre (TITIC), BengaluruJan 2025Flavor creation and application for IndiaOperational
5-for-1 stock splitEffective 1 Oct 2025To improve liquidity and market valuationCompleted
Dividend raiseFY2025Year-end forecast raised ¥24→¥28 (post-split)Paid June 2026
Iwata pharmaceutical-intermediate expansionCompleted H1 FY2025Increased supply capacityCompleted
New Iwata GMP intermediate plantAnnounced FY2025¥8bn investmentUnder construction
Quality-management upgrade (Fine Chemicals)FY2025Jointly with major client; shipments resumed Q4Completed / ramping
Global ERP (SAP) roll-outFY2025–FY2026France (FY2025, disruptive), Germany (FY2026, SG&A burden)Ongoing
Zhangjiagang (China) consolidationFY2025New consolidated subsidiaryCompleted
New R&D centre, JapanAnnounced 2026Land acquired FY2025Planning/construction
Dubai creative centre2,026MENA fine fragranceOpening 2026
Brazil affiliate expansion2025–2026Market penetration, partnershipsOngoing
Policy-shareholding reductionOngoing¥4.4bn gains in FY2025Ongoing
Leadership transitionJun 2026Mizuno President & COOCompleted
Next medium-term planExpected 2027Successor to NGP-2Pending

Guidance (FY2026, issued 15 May 2026; reaffirmed with Q1 per RTTNews)

MetricFY2025 actualFY2026 guidanceChange
Net sales¥225.1bn¥240.0bn+6.6%
Gross profit¥72.9bn¥80.1bn+9.9%
Gross margin32.4%33.4%+1.0pt
SG&A¥64.8bn¥69.1bn+6.7%
Operating profit¥8.1bn¥11.0bn+35.3%
Ordinary profit¥9.5bn¥11.5bn+20.9%
Net income to owners¥9.5bn¥9.4bn−1.3%
EPS¥97.72¥96.43−1.3%
FX assumptionsUSD 150 / EUR 169USD 150 / EUR 170—

Management's operating-profit bridge to FY2026: ¥8.1bn + sales growth ¥5.3bn + cost of sales ¥1.9bn − SG&A ¥4.3bn − Middle East situation impact ¥5.0bn + improvements (price adjustments) ¥5.0bn + FX ¥0.0 = ¥11.0bn. The explicit ¥5.0bn Middle East headwind (raw-material and logistics costs) offset by ¥5.0bn of pricing is a key execution risk.

Products & Services

Note: Takasago does not publish SKU-level pricing or launch dates for most compounds (bespoke B2B products). Named products below are those identifiable in public sources; launch years are given only where verified.

Flavor Division (54.5% of FY2025 sales)

Product lineDescriptionTarget customersNotes
Beverage flavorsFlavors for soft drinks, RTD tea/coffee, juices, functional and alcoholic beveragesJapanese and Chinese beverage majors, global bottlersStrongest growth driver in Japan and China in FY2025; Japan segment sales +4.6% on beverage shipments
Dairy flavorsMilk, yogurt, ice-cream and dairy-alternative flavor systemsDairy processors, retailer private labels (Europe: products supplied to customers of Aldi, Lidl, Edeka, Rewe per 2017 consular speech)Takasago Europe (Zülpich) is a key flavor/extract site
Savory flavorsSeasonings, reaction flavors, umami/kokumi systems for processed foods, snacks, noodlesProcessed-food manufacturersCited as an emerging-market growth area in FY2026 guidance
Confectionery flavorsCandy, gum, bakery flavorsConfectionery manufacturers—
Oral-care flavorsMint and cooling flavors for toothpaste and mouthwash, leveraging in-house l-menthol and cooling agentsOral-care multinationalsCited as an emerging-market growth driver for FY2026
Taste modulationFlavor-enhancing and masking solutions (e.g., salt/sugar reduction, bitterness masking); "LacteboosT" listed among Aroma/Flavor brands by GlobalDataHealth-oriented F&BSpecific specs not publicly disclosed
Natural extractsPlant and natural extractsF&B companies—

Pricing model: per-kg, bespoke. Flavor operating margin 4.2% (FY2025). FY2026F sales ¥126.0bn (+2.8% per company rounding, +3.3bn).

Fragrance Division (33.7%)

Product lineDescriptionTarget customersNotes
Fabric-care fragrancesFragrances for detergents, softeners, laundry beads; encapsulation and long-lasting technologiesFMCG majors; Chinese and Southeast Asian household-product companiesFY2025 growth driver in China and Southeast Asia
Home & air-care fragrancesAir fresheners, candles, surface cleanersFMCGFY2026 growth focus, especially Americas
Hair & personal-care fragrancesShampoos, conditioners, soaps, body wash, deodorantsFMCGFY2026 Americas growth driver
Fine fragrancePerfume and cologne creationPrestige and masstige perfume houses, MENA brandsNew Dubai creative centre (2026) targets MENA fine fragrance; Mumbai centre (2024) serves Indian market
Fragrance basesPre-compounded bases (US: Wessel Fragrances heritage)Smaller perfumers and manufacturers—

Fragrance technical themes cited by the company: "emotion, performance and green chemistry" (Cosmetics & Toiletries, 2026). FY2025 margin 0.8%; FY2026F sales ¥79.1bn, operating profit ¥2.6bn.

Aroma Ingredients Division (7.2%)

ProductDescriptionNotes
l-Menthol (synthetic, asymmetric)Nature-identical l-menthol made via BINAP-catalysed asymmetric synthesisFlagship molecule; foundation of Noyori collaboration
Cooling agents / sensatesCooling, warming and tingling compounds (Takasago's "Coolact" family is the widely known trade name; GlobalData lists "Sensates" as a product brand)Used in oral care, confectionery, cosmetics, tobacco alternatives
Specialty aroma chemicalsChiral and specialty molecules (e.g., musks, citronellal derivatives) sold to F&F industryFY2025: "specialty products remain steady"

FY2025 sales ¥16.2bn; operating margin 12.3% (down from 16.6% on key raw-material price increases). FY2026F operating profit ¥1.5bn.

Fine Chemicals Division (4.0%)

ProductDescriptionNotes
Pharmaceutical intermediates (GMP)Chiral intermediates manufactured for pharmaceutical customers, exported to Europe and the US (via US subsidiary)Highly concentrated client exposure; shipments postponed FY2025 for quality-system upgrade, resumed Q4; ¥8bn new GMP intermediate plant at Iwata
Asymmetric catalysts and ligandsBINAP, SEGPHOS-family ligands and metal complexes for asymmetric hydrogenationLicensing/sale to pharma and fine-chemical manufacturers
Electronic materialsOrganic materials for electronics (historically photoconductors)GlobalData lists "photoconductors"
Continuous-flow manufacturingProcess capability highlighted by JCRJCR (2023) cites strength in continuous-flow manufacturing

FY2025 sales ¥9.1bn; operating loss ¥0.8bn. FY2026F sales ¥17.0bn, operating profit ¥0.6bn.

Others

Real-estate leasing (¥1.4bn sales, ¥1.2bn operating profit, FY2025) — stable, non-core.

Financial Narrative

Sources: Company Tanshin (net sales, operating profit, ordinary profit, net income — company-reported figures preferred); S&P Global Market Intelligence via StockAnalysis.com (gross profit, R&D, D&A, balance sheet, cash flow). Where S&P figures differ from company figures (e.g., FY2024 operating income ¥14.9bn per S&P vs ¥15.3bn company-reported, a classification difference), company figures are used.

Income statement

Ordinary profit (company-reported, JPY M): FY2023 4,707; FY2024 15,311; FY2025 9,511 (Kabuyoho).

Per-share data (JPY, split-adjusted for 5-for-1 split of 1 October 2025)

FY2024 and FY2025 EPS are company-reported (Tanshin / Matsui). FY2021–FY2023 EPS are derived (net income ÷ year-end shares outstanding of 98.17m, 97.28m, 97.37m). Diluted EPS: not presented by the company (no material dilutive securities) — "not publicly disclosed" as a separate figure.

Dividends per share (split-adjusted, JPY): FY2023: 14 (¥70 pre-split annual, Yahoo Finance April 2024); FY2024: 48 (¥240 pre-split: ¥80 interim + ¥160 year-end); FY2025: 52 (¥120 pre-split interim = ¥24 post-split, plus ¥28 post-split year-end; ¥260 pre-split equivalent); FY2026F: 52 (¥26 interim + ¥26 year-end).

Margins (%, derived)

Revenue CAGR FY2021–FY2025 (4 years): 8.5% (derived). Much of this is yen depreciation: average USD/JPY moved from roughly ¥112 (FY2021) to ¥150 (FY2025), so constant-currency growth is materially lower (company does not disclose a constant-currency series).

Commentary. The five-year record shows a business whose top line has grown strongly in yen but whose profitability has oscillated in a 1–7% operating-margin band. Gross margin compressed in FY2022–FY2023 as raw-material and energy inflation outpaced pricing (gross margin fell 2.7 points), then recovered 5.0 points in FY2024 on product-mix optimisation, lower raw-material prices and high-margin pharmaceutical-intermediate exports. FY2025 margin compression (−1.4 points gross, −3.1 points operating) was driven by: lost fine-chemicals volume (high-margin), US subsidiary volume decline, yen-driven raw-material import costs in Japan, US tariff policy (¥2.3bn headwind in management's bridge) and SG&A growth of 4.4% (ERP and organisational strengthening). Management's FY2025 operating-profit bridge: FY2024 ¥15.3bn → special factors −¥1.6bn → net sales −¥0.4bn → cost of sales −¥2.2bn → SG&A −¥2.9bn → US tariffs −¥2.3bn → FX and others +¥2.2bn → FY2025 ¥8.1bn.

Balance sheet

Company-reported equity ratio: 55.0% (31 Mar 2025), 56.6% (31 Mar 2026); FY2026F 53.4%. Goodwill is not separately disclosed by the aggregator and appears immaterial. Total assets rose further to ¥285.1bn at 30 June 2026 (S&P), with net debt ¥46.7bn.

Commentary. The balance sheet is conservatively financed (equity ratio ~56%, debt/equity ~0.4x) but working-capital intensive: inventory has grown 35% in four years to ¥66.9bn. Net debt jumped ¥18.1bn in FY2025 as cash fell ¥16.0bn on a ¥19.3bn capex programme (including ¥10.4bn of land) and weak operating cash flow. A material asset not captured in net debt is the portfolio of "policy-held" (cross-shareholding) equities, equivalent to 12.8% of net assets at 31 March 2026 (≈ ¥20bn, derived), which management is reducing toward 10% — a source of non-operating gains (¥4.4bn gain on sale of investment securities in FY2025).

Cash flow

Company-reported FY2025 cash flows: operating ¥4,271m; investing −¥16,222m; financing −¥4,645m; closing cash ¥19,572m (Tanshin, 15 May 2026). Dividends paid: not separately verified (derived estimate ≈ ¥5.3–5.5bn in FY2025 based on ¥160 pre-split year-end FY2024 and ¥120 pre-split interim FY2025 on ~19.5m pre-split shares). Buybacks: negligible over five years (treasury stock roughly stable at ¥1.6–1.7bn; shares outstanding 98.17m → 97.48m), so not material.

Commentary. Cash conversion is the weakest part of the financial profile. FY2025 operating cash flow of ¥4.3bn (vs net income ¥9.5bn) was depressed by a ¥4.2bn inventory build, ¥2.4bn receivables build, ¥3.7bn payables reduction and ¥4.4bn of non-cash investment gains. Free cash flow was −¥15.0bn, the worst in the five-year series, funded by cash drawdown and modest borrowing. With FY2026 capex likely elevated (Iwata GMP plant, new R&D centre, Dubai), FCF recovery depends on working-capital release.

Ratios (derived unless stated)

ROE for FY2024 (9.8%) and FY2025 (6.4%) are company-reported; others use average equity (FY2021 uses year-end equity). ROIC uses year-end invested capital (net assets + net debt). S&P reports trailing ROIC 2.96% and WACC 4.71% (September 2026), implying value-dilutive returns at the current earnings run-rate.

Commentary. Returns sit below the company's own cost-of-capital thinking (NGP-2 targets ROE ≥8%). FY2024 is the only year in the five that met the target. The cash conversion cycle of ~207 days in FY2025 is long even for the F&F industry, where inventory-heavy natural raw materials are normal; a return to ~180 days would release roughly ¥15–16bn of cash (derived), which is the single largest internal lever for FCF and ROIC.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

BusinessFY2024FY2025FY2026F

Flavor net sales (JPY Bn)

119.8122.6126.0

Fragrance net sales (JPY Bn)

74.575.879.1

Aroma Ingredients net sales (JPY Bn)

15.716.216.5

Fine Chemicals net sales (JPY Bn)

17.89.117.0

Others net sales (JPY Bn)

1.41.41.4

Total net sales (JPY Bn)

229.2225.1240.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

BusinessFY2024FY2025FY2026F

Flavor operating profit (JPY Bn)

5.25.25.1

Fragrance operating profit (JPY Bn)

2.00.62.6

Aroma Ingredients operating profit (JPY Bn)

2.62.01.5

Fine Chemicals operating profit (JPY Bn)

4.4-0.80.6

Others operating profit (JPY Bn)

1.21.21.2

Total operating profit (JPY Bn)

15.38.111.0

Segment Revenue

BusinessFY2024 OP margin %FY2025 OP margin %FY2025 YoY sales growth %FY2025 share of sales %FY2024 share of sales %

Flavor

4.34.22.354.552.3

Fragrance

2.70.81.733.732.5

Aroma Ingredients

16.612.33.27.26.8

Fine Chemicals

24.7-8.8-48.94.07.8

Others (real estate)

85.785.70.00.60.6

Group

6.73.6-1.8100.0100.0

Revenue by Segment by Region

RegionFY2024FY2025FY2026F

Japan net sales (JPY Bn)

73.677.077.5

Americas net sales (JPY Bn)

66.555.665.2

EMEA net sales (JPY Bn)

39.342.442.9

Asia Pacific net sales (JPY Bn)

49.850.254.4

Total net sales (JPY Bn)

229.2225.1240.0

Results by Segment by Region

RegionFY2024FY2025FY2026F

Japan operating profit (JPY Bn)

4.50.62.0

Americas operating profit (JPY Bn)

2.60.92.6

EMEA operating profit (JPY Bn)

2.50.80.1

Asia Pacific operating profit (JPY Bn)

4.95.76.2

Adjustments (JPY Bn)

0.90.20

Total operating profit (JPY Bn)

15.38.111.0

Segment Revenue (FY2024 OP margin %–FY2025 share %)

RegionFY2024 OP margin %FY2025 OP margin %FY2025 YoY sales growth %FY2025 share %

Japan

6.10.84.634.2

Americas

3.91.6-16.424.7

EMEA

6.41.97.918.8

Asia Pacific

9.811.40.822.3

Results by Segment (Quarterly)

MetricQ1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026

Net sales (JPY Mn)

57,94356,52454,18956,43666,165

Operating profit (JPY Mn)

3,9482,2611,1737503,900

Ordinary profit (JPY Mn)

4,0172,7132,0547274,244

Net income to owners (JPY Mn)

2,8332,5631,3552,7743,245

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Net sales (JPY Mn)

162,440186,792195,940229,207225,092

Revenue growth YoY (%)

8.015.04.917.0-1.8

Gross profit (JPY Mn)

51,12954,43756,47777,39772,913

R&D expense (JPY Mn)

12,88814,16615,65017,66417,494

Operating profit, company-reported (JPY Mn)

8,8135,9482,31615,3418,132

D&A (JPY Mn)

6,9127,3787,8608,1148,756

EBITDA, derived OP+D&A (JPY Mn)

15,72513,32610,17623,45516,888

Pre-tax income (JPY Mn)

11,0018,5554,91017,68913,713

Net income to owners (JPY Mn)

8,9097,3932,69813,3259,525

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Basic EPS (JPY, split-adjusted)

90.775.627.7136.7897.72

Book value per share (JPY)

1,106.331,235.721,325.421,479.721,573.54

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

31.529.128.833.832.4

Operating margin (%)

5.43.21.26.73.6

EBITDA margin (%)

9.77.15.210.27.5

Net margin (%)

5.54.01.45.84.2

R&D / sales (%)

7.97.68.07.77.8

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (JPY Mn)

196,841212,079228,427262,174271,147

Cash and equivalents (JPY Mn)

16,14614,96918,33335,59019,578

Receivables (JPY Mn)

38,02941,75148,14452,62556,169

Inventory (JPY Mn)

49,40455,59555,45561,19266,870

PP&E (JPY Mn)

58,99960,98465,08371,08184,542

Intangible assets incl goodwill (JPY Mn)

2,8653,9884,7104,9225,509

Short-term debt incl current LTD (JPY Mn)

26,63529,81433,40838,51340,339

Long-term debt excl leases (JPY Mn)

16,91914,97013,32719,55419,597

Total debt incl leases (JPY Mn)

43,55444,78446,73560,70762,774

Net debt (JPY Mn)

27,40829,81528,40225,11743,196

Owners' equity (JPY Mn)

108,610120,210129,054144,202153,414

Total net assets incl minorities (JPY Mn)

110,294121,952130,879146,393156,049

Working capital (JPY Mn)

49,77755,90856,97074,64169,341

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (JPY Mn)

11,5685,82110,01118,9224,271

Capital expenditure (JPY Mn)

6,7645,0146,04111,30219,261

Free cash flow, derived (JPY Mn)

4,8048073,9707,620-14,990

Net debt issued or repaid (JPY Mn)

-8783301,6059,7811,741

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

8.26.52.29.86.4

ROA (%)

4.53.61.25.43.6

ROIC, NOPAT at 30% tax (%)

4.52.71.06.32.9

Current ratio (x)

1.871.911.821.931.88

Debt to equity (x)

0.400.370.360.420.41

Net debt to EBITDA (x)

1.742.242.791.072.56

Interest coverage, OP/interest (x)

18.412.74.121.59.2

Asset turnover (x)

0.830.910.890.930.84

Days sales outstanding

85.581.689.783.891.1

Days inventory outstanding

162.0153.3145.1147.1160.4

Days payables outstanding

56.349.349.652.644.7

Cash conversion cycle (days)

191.2185.6185.2178.3206.8

Revenue by Region

RegionFY2024FY2025FY2026F

Japan (JPY Bn)

73.677.077.5

Americas (JPY Bn)

66.555.665.2

EMEA (JPY Bn)

39.342.442.9

Asia Pacific (JPY Bn)

49.850.254.4

Revenue by Region (%)

Region (%)FY2025 YoY growth %FY2026F YoY growth %

Japan

4.60.6

Americas

-16.417.3

EMEA

7.91.2

Asia Pacific

0.88.4

Revenue by Region (9M FY2024–9M FY2025)

Region9M FY20249M FY2025

Japan (JPY Bn)

55.758.1

Americas (JPY Bn)

52.642.3

EMEA (JPY Bn)

29.830.8

Asia Pacific, derived (JPY Bn)

37.637.5

Region Overview

RegionFlavorFragranceAroma IngredientsFine Chemicals

Japan

Beverage strength (FY2025 driver)

Domestic FMCG

Production base (menthol, specialty)

Iwata plant; exports of intermediates to US/Europe

Americas

Beverage flavors (US)

Hair care, home care (FY2026 growth)

Distribution

US subsidiary receives and sells pharmaceutical intermediates

EMEA

Strong (Germany, Zülpich)

France (ERP disruption FY2025); fine fragrance; Dubai (2026)

Strong

Customers in Europe

Asia Pacific

Beverages (China), savory and oral care (emerging markets, India)

Fabric care (China, Southeast Asia)

——

Valuation Snapshot

MetricValueSource

Share price

¥1,252 (2 Oct 2026)

Kabuyoho

Market cap

¥126.2bn

Kabuyoho

Enterprise value

¥173.6bn (11 Sep 2026)

StockAnalysis

P/E (forecast FY2026)

13.0x

Kabuyoho

P/E (trailing)

12.5x

StockAnalysis (11 Sep 2026)

P/B

0.78x

Kabuyoho

EV/EBITDA (trailing)

10.0x

StockAnalysis

EV/Sales (trailing)

0.74x

StockAnalysis

Dividend yield (forecast)

4.15% (¥52)

Kabuyoho

Beta (5Y)

0.41

StockAnalysis

52-week change

−22.3% (to 11 Sep 2026)

StockAnalysis

50-day / 200-day MA

¥1,241 / ¥1,294 (11 Sep 2026)

StockAnalysis

Altman Z / Piotroski F

2.38 / 4

StockAnalysis

Share Price & Returns

PeriodPerformanceBasis

1 year

≈ −22%

StockAnalysis (Sep 2026)

~2.5 years

≈ +86%

¥3,365 pre-split (≈¥673 split-adjusted) on 23 Apr 2024 (Yahoo) vs ¥1,252 on 2 Oct 2026 (derived)

Mid-2025 snapshot

+85% over prior 365 days at ¥6,650 pre-split (≈¥1,330 adjusted)

Stockopedia

Peer Comparison

CompanyP/E (approx.)EV/EBITDA (approx.)P/B (approx.)

Takasago

13.010.00.78

Givaudan

~30

~20

~7

Symrise

~25–30

~15

~3

T. Hasegawa

~20

~10

~1.3

Capital Markets

ItemValueSource

Number of analysts

2

Simply Wall St

Consensus rating

3.00 (neutral on 5-point scale)

Kabuyoho (IFIS), Oct 2026

Consensus target price

¥1,550 (+23.8% vs ¥1,252)

Kabuyoho

Consensus ordinary profit FY2026

¥13.5bn (+41.9%) vs company ¥11.5bn

Kabuyoho

Consensus ordinary profit path FY2026

H1 ¥7.58bn; 9M ¥10.76bn; FY ¥13.5bn

Kabuyoho

Sponsored research

Shared Research (updated 19 Jun 2026)

Shared Research

Per-Share Data and Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026F

DPS split-adjusted (JPY)

14485252

Payout ratio (%)

50.635.153.253.9

DOE (%)

1.13.43.43.3

Credit Ratings

AgencyRatingOutlookLast action

JCR

A- (Long-term Issuer)

Positive

21 Nov 2025 (outlook raised from Stable)

Moody's

Not rated

——

S&P

Not rated

——

Fitch

Not rated

——

Bucket Details

BucketAmount

Short-term borrowings

32,338

Current portion of long-term debt (due within 1 year)

8,001

Long-term debt (due after 1 year)

19,597

Long-term lease liabilities

2,838

Total debt

62,774

Analyst Conclusions

Management guidance (FY2026, April 2026 – March 2027)

Net sales ¥240.0bn (+6.6%), operating profit ¥11.0bn (+35.3%), ordinary profit ¥11.5bn (+20.9%), net income ¥9.4bn (−1.3%), EPS ¥96.43, DPS ¥52. Q1 delivered 27.6% of sales guidance and 36.9% of ordinary-profit guidance, ahead of the prior-year pace (40.2% in Q1 FY2025 but against a declining full year).

Consensus expectations

Consensus ordinary profit of ¥13.5bn exceeds company guidance by ¥2.0bn (17%), implying the market expects either a faster fine-chemicals ramp or smaller Middle East cost headwinds. Target price ¥1,550.

Bull case

  1. Fine-chemicals normalisation is underpriced. FY2024 showed ¥4.4bn operating profit on ¥17.8bn sales; FY2026 guidance assumes only ¥0.6bn on ¥17.0bn. A partial return toward FY2024 margins would add ¥2–3bn to group operating profit.

  2. Q1 momentum. Record Q1 sales of ¥66.2bn (+14.2%) and net income +14.5% suggest the FY2025 trough (Q4 operating profit ¥0.75bn) is behind the company.

  3. Valuation and capital efficiency. At 0.78x P/B, 4.2% yield and 10x EV/EBITDA, the stock prices in sustained sub-par returns; working-capital release (¥15bn), continued cross-shareholding sales and a new medium-term plan under a new President could catalyse a re-rating toward 1x book (~¥1,600).

Bear case

  1. Structural margin gap persists. Even FY2024's record 6.7% operating margin is far below peers; Fragrance earns <1% and the company lacks scale to close the gap.

  2. Cost shocks and FX. The guidance already relies on ¥5.0bn of price increases to offset a ¥5.0bn Middle East headwind; any slippage, plus yen volatility (August 2026 intervention), threatens the ¥11.0bn target.

  3. Cash-flow strain. FCF of −¥15.0bn in FY2025 and a continuing investment programme (Iwata GMP, R&D centre, Dubai) push net debt higher (¥46.7bn at June 2026), while ROE guidance of 6.0% misses the NGP-2 target of 8%.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
13 Nov 2026H1 FY2026 results — fine-chemicals run-rate; consensus H1 ordinary profit ¥7.58bn
H2 FY2026Pricing realisation vs ¥5.0bn Middle East headwind
OngoingGerman ERP stabilisation; French subsidiary normalisation
2,026Dubai creative-centre launch; Iwata GMP plant progress
Feb 2027Q3 results — guidance revision risk (up or down)
Early 2027Announcement of next medium-term plan (post-NGP-2) under Mizuno; targets for ROE, margin, cross-shareholdings
May 2027FY2026 results; FY2027 guidance; dividend policy
Late 2027JCR annual review — potential upgrade to A from A-/Positive

Concluding analyst verdict

Takasago International is a technically distinctive but financially underperforming member of the global flavor-and-fragrance industry. Its genuine differentiators — Japan's leading domestic position, a profitable Asia Pacific franchise, Noyori-derived chiral chemistry, and a conservative A-/Positive balance sheet — have not translated into consistent shareholder returns. Over five years the company has grown yen sales at an 8.5% CAGR, but operating margins have ranged from 1.2% to 6.7%, ROE has met the 8% target in only one year, and FY2025 free cash flow was deeply negative at −¥15.0bn.

FY2025 should be viewed as a cyclical and execution-driven trough rather than a structural collapse. The ¥7.2bn operating-profit decline is largely attributable to identifiable, partly reversible factors: the postponement of pharmaceutical-intermediate shipments during a client-driven quality upgrade (−¥5.2bn segment swing), a high US base, French ERP disruption and US tariffs. The record Q1 FY2026 sales and net-income growth support management's ¥11.0bn operating-profit guidance, and the consensus (¥13.5bn ordinary profit) is more optimistic still.

The investment debate therefore turns on whether the new leadership team can convert technical assets into durable profitability. Monitorables are concrete: fine-chemicals margins returning toward FY2024 levels, Fragrance margin rising above 3%, the cash conversion cycle falling from ~207 days toward 180, and cross-shareholdings reaching the 10% target. At 0.78x book and a 4.2% dividend yield underpinned by a DOE floor, the downside appears cushioned, while a credible post-NGP-2 plan could close part of the valuation gap to book value.

Analyst stance: Neutral-to-constructive. The stock offers value and income with recovery optionality, but a sustained re-rating requires proof — most likely visible in the H1 and full-year FY2026 results and the next medium-term plan — that margin and cash-flow improvements are structural rather than cyclical.


Source register (principal)

SourceDateUsed for
Takasago, Consolidated Financial Results for FY ended 31 Mar 2026 (Tanshin)15 May 2026Income, balance sheet, cash flow, shares, EPS, dividends
Takasago, Supplemental Information, Financial Results for FY202515 May 2026Segment/regional data, bridges, guidance, capital policy
Takasago, Q3 FY2025 Tanshin and Supplemental Information13 Feb 20269M data, guidance revision, Zhangjiagang consolidation
Takasago, Q1 FY2025 supplementary briefing (TSE)7 Aug 2025Q1 FY2025 data, market growth ~4%
Takasago, Notice of change in Representative Directors15 May 2026Leadership
JCR rating releases and rating list2021–2025Credit rating
S&P Global Market Intelligence via StockAnalysis.comJun–Sep 2026Five-year financial statements, valuation, ownership
Kabuyoho (IFIS)Jun–Oct 2026Price, market cap, consensus, forecast history
Matsui Securities2,026Quarterly results
RTTNews; Minkabu; EDINET DBAug 2026Q1 FY2026
Envalith (Annual Securities Report summary)Jul 2026R&D split, overseas sales, capex detail
Cosmetics & Toiletries2,026Strategy, Dubai, leadership
FilingReader (AI summaries of filings)2025–2026Corroboration of filings
Chemical Weekly; NRW Global Business; Consulate-General of Japan Düsseldorf; Cosmetics Business; Premium Beauty News2013–2024History and footprint
Wikipedia; Shared Research; Simply Wall St; GlobalData; DataInsightsMarket; OwlerVariousCorporate profile, executives, employees

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundSource

Satoshi Masumura

Representative Director, Chairman & CEO (from 25 Jun 2026)

President since 15 May 2014 (President & CEO to June 2026); previously General Manager of Safety Division (from 2018 per profile); age 67 (Simply Wall St) ; owns ~0.16% of shares

Simply Wall St; company release

Naoki Mizuno

Representative Director, President & COO (from 25 Jun 2026)

Joined 1985; GM of Fragrance & Aroma Ingredients Division; President, Takasago Aromas Co., Ltd.; Chairman, Takasago International (Zhangjiagang); SVP overseeing corporate supply-chain management; Senshu University graduate; held 65,120 shares at announcement

FilingReader; Cosmetics & Toiletries

Kenichi Somekawa

Director, Senior Vice President, GM Flavor Division; Chairman, Takasago International (Guangzhou)

Age ~63 (GlobalData, 2024)

GlobalData; DataInsightsMarket

Shigeki Kawabata

Senior Vice President, Corporate Strategy, Planning, Legal & IP Division

—

DataInsightsMarket

Tatsuya Yamagata

Senior Vice President, Global Integration HQ; Global SAP Management Department

Leads ERP programme

DataInsightsMarket

Takayuki Kibayashi

Vice President, GM Corporate Administration Division; Director of Finance & Accounting

De facto finance head

Simply Wall St; DataInsightsMarket

Hirokazu Isono

Executive, human capital / global workforce

—

DataInsightsMarket

Paul Ireland

President, Worldwide Fragrance Division

Cited at Mumbai opening (2024)

Chemical Weekly

Governance Overview

FeatureDetail

Governance form

Company with Audit & Supervisory Board (kansayaku-type), per board-member titles ("Outside Audit & Supervisory Board Member") on Simply Wall St

Chair/CEO separation

Not separated: Masumura is Chairman and CEO; operating leadership separated via Mizuno as President & COO

Board tenure

Average board tenure ~8.4–8.6 years; management ~8.9–9.1 years (Simply Wall St)

Notable historical director

Ryōji Noyori (Nobel laureate, 2001) served on the board (Wikipedia; 2017 consular speech)

Restructuring

Board of directors restructured alongside the June 2026 leadership change (FilingReader)

Board & Management Changes

DateChangeContext

15 May 2026 (announced) / 25 Jun 2026 (effective)

Naoki Mizuno succeeds Masumura as President (COO); Masumura becomes Chairman & CEO

Final year of NGP-2; preparation of next medium-term plan and Vision 2040; follows FY2025 profit drop of 47%

Major Shareholders

Holder typeStakeSource

Institutions

37.94%

StockAnalysis (S&P), Sep 2026

Insiders

0.60%

StockAnalysis (S&P), Sep 2026

Treasury shares

3.24% (3,265,935 of 100,761,985)

Tanshin, 31 Mar 2026

Float

90.94m shares

StockAnalysis

Competitive Landscape

Key Competitors

CompetitorHQSegments where competesApprox. scale (latest known)Relative positioning

Givaudan

Switzerland

Flavor, Fragrance, Ingredients

~CHF 7.4bn sales (2024)

Global #1; scale, margins (~23% EBITDA) far above Takasago

dsm-firmenich

Switzerland/Netherlands

Flavor, Fragrance, Ingredients, Nutrition

~€12.8bn group sales (2024)

Formed 2023; broadest portfolio

IFF (International Flavors & Fragrances)

USA

Flavor, Fragrance, Ingredients

~USD 11.5bn sales (2024)

Global #3; restructuring/divestitures

Symrise

Germany

Flavor (Taste, Nutrition & Health), Fragrance (Scent & Care), menthol

~€5.0bn sales (2024)

Direct menthol competitor; ~20% EBITDA margin

Mane

France (private)

Flavor, Fragrance

~€1.9bn (approx., 2024)

Private family-owned; similar mid-tier position

Robertet

France

Naturals, Fragrance, Flavor

~€0.8bn (approx., 2024)

Natural raw-material specialist

T. Hasegawa

Japan

Flavor, Fragrance

~¥75–80bn (approx., FY Sep 2024)

Main domestic rival; higher margins in flavors

Ogawa & Co.

Japan (private)

Flavor, Fragrance

—

Domestic rival

Sensient Technologies

USA

Flavors, colors

~USD 1.6bn (approx., 2024)

Overlap in flavors

Kerry Group (Taste & Nutrition)

Ireland

Flavors, taste systems

~€6–7bn T&N segment (approx.)

Food-systems competitor

BASF Aroma Ingredients

Germany

Menthol, aroma chemicals

Segment not separately disclosed

Synthetic menthol competitor

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricTakasago (FY2025, Mar-26)Givaudan (2024)Symrise (2024)IFF (2024)

Revenue (USD Bn, approx.)

1.508.45.411.5

Reported revenue growth (%)

-1.8

~7.9

~6.8

~0

EBITDA margin (%)

7.5

~23

~20

~19 (adjusted)

R&D intensity (%)

7.8

~7.5

~5.5

~5.5

Company Snapshot

$1,503.6M

Revenue

4,154

Employees

$840M

Market Cap

1920

Founded

Tokyo, Japan

Headquarters

SWOT Analysis

Strengths

  • Japan's largest F&F company — confirmed by JCR rating releases and Shared Research; #1 domestic share.
  • Profitable Asia Pacific franchise — ¥5.7bn operating profit at 11.4% margin in FY2025, up ¥0.7bn while other regions declined.
  • Proprietary asymmetric-synthesis technology — Noyori-derived BINAP catalysis underpinning l-menthol and chiral intermediates; Aroma Ingredients margin 12.3–16.6%.
  • Solid balance sheet — equity ratio 56.6%, debt/equity 0.41x (31 March 2026); JCR A-, outlook Positive (November 2025).
  • Sustained R&D investment — ¥17.5bn (7.8% of sales) in FY2025, rising from ¥12.9bn in FY2021.
  • Geographic diversification — 66% overseas sales; four regions each 19–34% of sales.
  • Shareholder-return commitment — DPS held at ¥52 (post-split) despite 47% OP decline; DOE 3.4%.

Weaknesses

  • Low profitability — group operating margin 3.6% (FY2025) vs ~20%+ EBITDA margins at leaders; ROIC ~2.9% below S&P-estimated WACC of 4.7%.
  • Fragrance margin near zero — 0.8% operating margin on ¥75.8bn sales (FY2025).
  • Weak cash conversion — OCF ¥4.3bn vs net income ¥9.5bn; FCF −¥15.0bn (FY2025); CCC ~207 days.
  • Fine-chemicals volatility — segment OP swung from +¥4.4bn to −¥0.8bn in one year on a single client-related quality issue.
  • ERP execution problems — French subsidiary fragrance shipments fell on new ERP implementation (FY2025); German ERP raising FY2026 SG&A.
  • Reliance on non-operating gains — ¥4.4bn gain on sale of investment securities supported FY2025 net income (46% of net income).

Opportunities

  • Fine-chemicals recovery — guided to ¥17.0bn sales (+87%) in FY2026; new ¥8bn Iwata GMP plant adds capacity.
  • MENA fine fragrance — Dubai creative centre opening 2026.
  • India and Southeast Asia — three Indian centres (Chennai, Mumbai, Bengaluru); FY2026 APAC sales forecast +8.4%.
  • Americas rebound — FY2026 Americas sales forecast +17.3% (pharma intermediates, US home care, beverages).
  • Balance-sheet efficiency — policy shareholdings at 12.8% of net assets (≈¥20bn) to be cut toward 10%; working-capital release potential ~¥15bn (derived).
  • Valuation re-rating — PBR 0.78x (October 2026) under TSE pressure to lift sub-1x PBR companies; consensus target ¥1,550 (≈24% above ¥1,252).
  • Leadership renewal — new President (June 2026) and next medium-term plan (2027) as a platform for portfolio and margin reform.

Threats

  • Raw-material and geopolitical cost shocks — management assumes ¥5.0bn Middle East impact in FY2026.
  • US tariff policy — ¥2.3bn OP impact in FY2025.
  • Competitive scale disadvantage — leaders (Givaudan ~CHF 7.4bn sales) dominate FMCG core lists.
  • Client concentration in pharma intermediates — quality-system issue in FY2025 shows dependency on one major client.
  • FX volatility — August 2026 Japan–US joint intervention to support the yen; Japan segment margin highly sensitive to import costs.
  • Synthetic menthol competition — Symrise and BASF capacity in a commoditising molecule; Aroma Ingredients margin already fell from 16.6% to 12.3%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 May 2025FY2024 results: record net sales ¥229.2bn (+17.0%), OP ¥15.3bn (+562.4%), net income ¥13.3bnPeak earnings year; ROE 9.8% exceeded target
15 May 2025FY2025 initial guidance: sales ¥230.0bn, OP ¥12.5bnImplied 18.5% OP decline, signalling fine-chem normalisation
15 May 20255-for-1 stock split announced (effective 1 Oct 2025)Liquidity/valuation initiative
Jun 2025Corporate expansion at Takasago International (Singapore)APAC hub investment
7 Aug 2025Q1 FY2025: sales ¥57.9bn (+4.5%), OP ¥3.9bn (−1.7%), net income ¥2.8bn (−27.3%)Fine-chem intermediate exports to group companies declined; global F&F market said to grow ~4% annually
30 Sep / 1 Oct 2025Stock split takes effectShare count ×5
13 Nov 2025H1 FY2025: sales ¥114.5bn (+0.8%), OP ¥6.2bn (−22.4%)US subsidiary and pharma-intermediate weakness
Nov 2025Year-end dividend forecast raised ¥24→¥28 (post-split)Shareholder-return commitment despite profit decline
H1 FY2025Iwata pharmaceutical-intermediate expansion completed; ¥8bn new GMP plantFine-chem capacity build
21 Nov 2025JCR affirms A-, outlook to PositiveCredit-quality recognition
13 Feb 2026Q3 FY2025: 9M sales ¥168.7bn (−4.0%), OP ¥7.4bn (−43.6%); FY guidance cut to sales ¥225.0bnGuidance revision; US and France weakness
FY2025Zhangjiagang subsidiary consolidatedChina expansion
FY2025French subsidiary ERP go-live disrupts fragrance shipmentsExecution issue
FY2025¥19.3bn capex including ¥10.4bn landInvestment cycle peak
Early 20262026 Fragrance Leaders feature: Dubai creative centre, Brazil growth, AIStrategy articulation
15 May 2026FY2025 results: sales ¥225.1bn (−1.8%), OP ¥8.1bn (−47.0%), net income ¥9.5bn (−28.5%)Earnings trough relative to FY2024
15 May 2026FY2026 guidance: sales ¥240.0bn, OP ¥11.0bn; ¥5.0bn Middle East headwind assumedRecovery guidance
15 May 2026DPS ¥52 maintained for FY2026; payout 53.9%, DOE 3.3%Stable dividend
15 May 2026Naoki Mizuno nominated President & COOLeadership succession
15 May 2026New Dubai base and Japanese R&D centre highlightedGrowth investments
19 Jun 2026Shared Research updates full-year reportSponsored coverage
25 Jun 2026AGM approves board; Mizuno President & COO, Masumura Chairman & CEOGovernance transition
26 Jun 2026FY2025 year-end dividend paid—
Jun 2026Annual Securities Report filed: R&D ¥17.5bn; overseas sales 66%Disclosure
Early Aug 2026Japan–US joint currency intervention to support the yen (macro)FX translation and import-cost implications
6 Aug 2026Q1 FY2026: record sales ¥66.2bn (+14.2%), ordinary profit ¥4.24bn (+5.6%), net income ¥3.2bn (+14.5%), EPS ¥33.29Strong start; 36.9% progress vs ordinary-profit guidance
29 Sep 2026Ex-dividend date for interim dividend—
13 Nov 2026 (scheduled)H1 FY2026 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Revenue by Segment: Total net sales to Fine Chemicals net sales: Total net sales rose from JPY 229.2 Bn in FY2024 to JPY 240 Bn in FY2026F.
Takasago International Corporation — Revenue by Segment: Total net sales to Fine Chemicals net sales
Series (JPY Bn)FY2024FY2025FY2026F
Total net sales229.2225.1240
Flavor net sales119.8122.6126
Fragrance net sales74.575.879.1
Aroma Ingredients net sales15.716.216.5
Fine Chemicals net sales17.89.117

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.